HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E].

Abstract
A 54-year-old man underwent abdominoperineal resection for rectal cancer. Adjuvant chemotherapy was not performed because of stage I cancer. Nine months after the operation, solitary liver metastasis, and elevated CEA and CA19-9, were found during the postoperative work-up. A combination chemotherapy of CPT-11 and UFT-E was performed before scheduled liver resection. 150 mg/m2 of CPT-11 was administered on days 1 and 15. 375 mg/m2/day of UFT-E was divided in half and administered on days 3-7, 10-14, 17-21, and 24-28 as one course of treatment. This regimen was repeated every 5 weeks. The patient had a grade 2 diarrhea and nentropenia during the treatment. Bowel obstruction was also observed after 5 courses of treatment, which required hospitalization. In addition, the liver metastasis had disappeared. There was no evidence of recurrence after 8 months of chemotherapy. It was suggested that CPT-11+UFT-E combination chemotherapy was effective for advanced colorectal cancer.
AuthorsTaishi Hata, Masataka Ikeda, Masakazu Ikenaga, Iwao Seshimo, Osamu Takayama, Hiroki Fukunaga, Masayoshi Yasui, Hirofumi Yamamoto, Masayuki Ohue, Mitsugu Sekimoto, Morito Monden
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 31 Issue 11 Pg. 1702-4 (Oct 2004) ISSN: 0385-0684 [Print] Japan
PMID15553688 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Tegafur
  • Uracil
  • Irinotecan
  • Camptothecin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Camptothecin (administration & dosage, analogs & derivatives)
  • Drug Administration Schedule
  • Humans
  • Irinotecan
  • Liver Neoplasms (drug therapy, secondary)
  • Male
  • Middle Aged
  • Rectal Neoplasms (pathology, surgery)
  • Tegafur (administration & dosage)
  • Uracil (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: